This work is an extension of our previous GWA-metabolomics study, in which the
quantitative high-throughput NMR metabolomics platform, used to quantify human
blood metabolites, was applied4 (link). In this study, we have utilized
the same platform to quantify 123 metabolite measures that represent a broad
molecular signature of systemic metabolism. The metabolite set covers multiple
metabolic pathways, including lipoprotein lipids and subclasses, fatty acids as
well as amino acids and glycolysis precursors. Most of the NMR-based
metabolomics analyses were performed with the comprehensive quantitative
serum/plasma platform described originally by Soininen et al.24 (link) and reviewed recently25 (link). This same platform was
used here to analyse samples in Estonian Genome Center of University of Tartu
Cohort (EGCUT), Finnish Twin Cohort, a subsample of FINRISK 1997 (FR97), Genetic
Predisposition of Coronary Heart Disease in Patients Verified with Coronary
Angiogram (COROGENE), Genetics of METabolic Syndrome, Helsinki Birth Cohort
Study (HBCS), Cooperative Health Research in the Region of Augsburg (KORA),
Northern Finland Birth Cohort 1966 (NFBC 1966), FINRISK subsample of incident
cardiovascular cases and controls (PredictCVD), EGCUT sub-cohort (PROTE) and
YFS. Metabolite-specific untransformed distributions and descriptive summary
statistics from the largest cohort, NFBC 1966, are presented inSupplementary Fig. 3 . Chemical shifts and
the coefficients of variation for inter-assay variability are presented inSupplementary Data 3 for each
metabolite. Here, the study was extended with Erasmus Rucphen Family Study
(ERF), Leiden Longevity Study (LLS) and Netherlands Twin Register (NTR) cohorts
for which the small-molecule information was available from another NMR-based
method (Supplementary Table 2 for
details)26 (link). Metabolite-specific untransformed distributions
and descriptive summary statistics for these measures from the ERF cohort are
given inSupplementary Fig. 4 .
Chemical shifts and the coefficients of variation for inter-assay variability
are presented inSupplementary Table
7 . The sample material was mostly serum, except for EGCUT, PROTE, NTR
and LLS in which the sample material was EDTA-plasma. The ERF cohort had
additional lipoprotein measures available through the method developed by Bruker
Ltd. (https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/MagneticResonance/NMR/brochures/lipo-analysis_apps.pdf ).
The terminology of this method utilized for lipoprotein analyses in ERF was
matched based on the lipoprotein particle size with the comprehensive
quantitative serum/plasma platform to enable meta-analyses. The vast majority of
blood samples were fasting, however, if a study did not have overnight fasting
samples, we corrected the fasting time effect by using R package gam and fitting
a smoothed spline to adjust for fasting. All metabolites were first adjusted for
age, sex, time from last meal, if applicable, and ten first principal components
from genomic data and the resulting residuals were transformed to normal
distribution by inverse rank-based normal transformation.
quantitative high-throughput NMR metabolomics platform, used to quantify human
blood metabolites, was applied4 (link). In this study, we have utilized
the same platform to quantify 123 metabolite measures that represent a broad
molecular signature of systemic metabolism. The metabolite set covers multiple
metabolic pathways, including lipoprotein lipids and subclasses, fatty acids as
well as amino acids and glycolysis precursors. Most of the NMR-based
metabolomics analyses were performed with the comprehensive quantitative
serum/plasma platform described originally by Soininen et al.24 (link) and reviewed recently25 (link). This same platform was
used here to analyse samples in Estonian Genome Center of University of Tartu
Cohort (EGCUT), Finnish Twin Cohort, a subsample of FINRISK 1997 (FR97), Genetic
Predisposition of Coronary Heart Disease in Patients Verified with Coronary
Angiogram (COROGENE), Genetics of METabolic Syndrome, Helsinki Birth Cohort
Study (HBCS), Cooperative Health Research in the Region of Augsburg (KORA),
Northern Finland Birth Cohort 1966 (NFBC 1966), FINRISK subsample of incident
cardiovascular cases and controls (PredictCVD), EGCUT sub-cohort (PROTE) and
YFS. Metabolite-specific untransformed distributions and descriptive summary
statistics from the largest cohort, NFBC 1966, are presented in
the coefficients of variation for inter-assay variability are presented in
metabolite. Here, the study was extended with Erasmus Rucphen Family Study
(ERF), Leiden Longevity Study (LLS) and Netherlands Twin Register (NTR) cohorts
for which the small-molecule information was available from another NMR-based
method (
details)26 (link). Metabolite-specific untransformed distributions
and descriptive summary statistics for these measures from the ERF cohort are
given in
Chemical shifts and the coefficients of variation for inter-assay variability
are presented in
7
and LLS in which the sample material was EDTA-plasma. The ERF cohort had
additional lipoprotein measures available through the method developed by Bruker
Ltd. (
The terminology of this method utilized for lipoprotein analyses in ERF was
matched based on the lipoprotein particle size with the comprehensive
quantitative serum/plasma platform to enable meta-analyses. The vast majority of
blood samples were fasting, however, if a study did not have overnight fasting
samples, we corrected the fasting time effect by using R package gam and fitting
a smoothed spline to adjust for fasting. All metabolites were first adjusted for
age, sex, time from last meal, if applicable, and ten first principal components
from genomic data and the resulting residuals were transformed to normal
distribution by inverse rank-based normal transformation.
Full text: Click here